Recent studies demonstrated a reduced expression of Fragile X Mental Retardation Protein (FMRP), an RNA binding protein and translation regulator, in the brain and peripheral lymphocytes of patients with schizophrenia. Low FMRP levels may be related to impaired neurodevelopmental processes and synaptic plasticity. Here, we studied the relationship between peripheral FMRP level, visual perception (contrast sensitivity, perceptual integration, motion/form perception), and neuropsychological functions in schizophrenia as measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results revealed that patients with schizophrenia displayed lower FMRP levels in peripheral lymphocytes as compared to control individuals. We found significant correlations between FMRP levels and contrast sensitivity at low spatial and high temporal frequencies, perceptual integration, and motion perception. The relationship between FMRP level and neuropsychological functions was less pronounced than that seen in the case of visual perception, with the greatest effect for RBANS attention. FMRP level was not related to contrast sensitivity at high spatial and low temporal frequencies and form perception. This pattern of data is reminiscent to that observed in patients with Fragile X Syndrome (FXS). These results suggest that FMRP may be implicated in the pathogenesis of schizophrenia, possibly via the regulation of neurodevelopment, plasticity, GABA-ergic, and glutamatergic neurotransmission.
Introduction
Research during the past decades revealed a characteristic and significant perceptual and neurocognitive dysfunction in schizophrenia. Extensive evidence suggests that deficits in executive functions, attention, memory, social cognition, and visual perception markedly contribute to the psychosocial outcome of the illness (Roder & Medalia, 2010; Sharma & Harvey, 2000) . However, the neurobiological mechanisms of neurocognitive and perceptual dysfunctions have not been clarified, and there is no satisfying treatment strategy.
Recently, we found preliminary evidence that molecular mechanisms implicated in intellectual and developmental disabilities may be related to cognition in schizophrenia, with a special reference to Fragile X Syndrome (FXS) (Kovács et al., 2013) . In FXS, the Fragile X Mental Retardation Protein (FMRP) is absent because of an extensive nucleotide triplet expansion, leading to neurodevelopmental and cognitive anomalies. FMRP can be detected in the soma and dendritic spines of neurons serving as a translational suppressor for genes encoding proteins essential for synaptic plasticity (Bear et al., 2008; O'Donnell & Warren, 2002; Rousseau et al., 2011) . There is increasing evidence that altered expression of FMRP and its mRNA characterizes various disorders, including premature ovarian insufficiency, fragile X-associated tremor/ataxia syndrome, autism, mood disorders, and schizophrenia (Bourgeois et al., 2009; Fatemi et al., 2010; Fatemi & Folsom, 2011; Hagerman et al., 2010) . Fatemi et al. (2010) found reduced FMRP expression in the lateral cerebellum of patients with schizophrenia and mood disorders. We confirmed these findings in peripheral lymphocytes of schizophrenia patients (Kovács et al., 2013) . In addition, low FMRP expression predicted earlier illness onset and decreased IQ, which may indicate the key role of FMRP in neurodevelopment and cognition (Kovács et al., 2013) .
In the present study, we aimed to extend these findings by investigating the cognitive and perceptual correlates of reduced peripheral FMRP in schizophrenia. We assessed neuropsychological functions and different aspects of visual perception. First, we examined immediate and delayed memory, attention, language, and visuospatial functions using the Repeatable Battery for the Assessment of Neuropsychological
